We use necessary cookies to make our website work. We also use optional statistical, functional and marketing cookies that you can choose to decline in your preference setting. For more information about the use of cookies or our use of data, see our Cookies notice or Privacy notice

Cookies settings I agree I refuse

Cookies information

Our site uses tools, such as cookies, to analyze and improve your experience. You can unsubscribe below:


We use tools, such as Google Analytics, to track web traffic and verify the effectiveness of our site.


Cookies required for essential services and features such as login forms, shopping cart integration and access control. Without them, our website cannot function properly and we cannot provide any services. Deactivation is not available.

These settings will be kept for 24h


23rd Annual Biotech in Europe Forum - Sachs Associates

23rd Annual Biotech in Europe Forum - Sachs Associates
Check the link
23rd Annual Biotech in Europe Forum - Sachs Associates

Bioxodes' CEO March Dechamps presents at the 23rd Annual Biotech in Europe Forum for Global Parntering & Investment, organised by Sachs Associates

CEO Marc Dechamps will present groundbreaking developments in Bioxodes' journey towards revolutionizing stroke care.
Our lead candidate Ir-CPI has a distinctive mode of action which provides a dual benefit by preventing blood clots, minimizing bleeding risks, and inhibiting neuroinflammatory events linked to intracerebral hemorrhage.